RARE CELL ANALYSIS USING SAMPLE SPLITTING AND DNA TAGS

• US 20080090239A1
• Filed: 06/13/2007
• Published: 04/17/2008
• Est. Priority Date: 06/14/2006
• Status: Abandoned Application

• Current Assignee: Gpb Scientific, LLC, Mehmet Toner
• Original Assignee: Gpb Scientific, LLC
• Inventors: SHOEMAKER, DANIEL, Krueger, Neil, Toner, Mehmet, Kapur, Ravi, Wang, Zihua, Gray, Darren, Fuchs, Martin
• Application Number:
  US11/762,747
• Publication Number:
  US 20080090239A1
• Time in Patent Office: Days
• US Class Current: 435/6.12
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: G01N 1/405 by adsorption or absorption
• CPC Class Codes: G01N 2015/1006 for cytology
• CPC Class Codes: G01N 2015/1029 Particle size
• CPC Class Codes: G01N 2800/385 Congenital anomalies
• CPC Class Codes: G01N 33/5005 involving human or animal cells immunoassay G01N33/56966; immunoassays of protozoa G01N33/56905; protozoa in screening assays C12Q1/025
• CPC Class Codes: G01N 33/5091 for testing the pathological state of an organism
• CPC Class Codes: G01N 33/57484 involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites

Abstract

Described herein are methods to diagnose or prognose cancer in a subject by enriching, detecting, and analyzing individual rare cells, e.g., epithelial cells, in a sample from the subject. Also described are methods for labeling regions of genomic DNA in individual cells in said mixed sample with different labels wherein each label is specific to each cell and quantifying the labeled regions of genomic DNA from each cell in the mixed sample. More particularly the method includes detecting the presence of gene mutations in individual rare cells in a subsample.

Claims

1. A method for diagnosing or prognosing cancer in a patient comprising:

splitting a rare cell-enriched biological sample, obtained at a time point from said patient, into a plurality of subsamples; and

performing a molecular analysis or a morphological analysis on one or more subsamples in said plurality of subsamples, wherein ten percent or more of the total number of cells in at least one of said one or more subsamples are rare cells, and a cancer diagnosis or prognosis for said patient is determined based on said molecular analysis or said morphological analysis.

2. The method of claim 1, wherein said one or more rare cells comprises an epithelial cell, a circulating tumor cell, an endothelial cell, or a stem cell.

3. The method of claim 2, wherein said one or more rare cells comprises an epithelial cell.

4. The method of claim 1, wherein said rare cell-enriched biological sample is a rare cell-enriched blood sample.

5. The method of claim 1, wherein at least one of said subsamples comprises about one to ten rare cells.

6. The method of claim 1, further comprising determining the fraction of said plurality of subsamples that comprises one or more rare cells.

7. The method of claim 1, wherein said rare cell-enriched biological sample was obtained by rare cell immunoaffinity separation of a biological sample from said patient.

8. The method of claim 7, wherein said rare cell immunoaffinity separation included flowing said biological sample from said patient through an array of obstacles coated with one or more antibodies that selectively bind to rare cells.

9. The method of claim 7, wherein the immunoaffinity separation comprised an EpCAM immunoaffinity separation.

10. The method of claim 7, wherein, prior to said immunoaffinity separation, said biological sample from said patient was flowed through an array of obstacles that selectively directs cells equal to or larger than a predetermined size to a first outlet and cells smaller than said predetermined size to a second outlet.

11. The method of claim 1, wherein said rare cell-enriched biological sample was obtained by size-based separation of rare cells present in a biological sample from said patient.

12. The method of claim 11, wherein said size-based separation of rare cells included flowing a biological sample from said patient through an array of obstacles that deflect particles based on hydrodynamic size.

13. The method of claim 12, wherein before said sized-based separation of rare cells, said biological sample from said patient was flowed through an array of obstacles coated with antibodies that selectively bind to rare cells.

14. The method of claim 1, wherein said molecular analysis comprises detecting the presence or absence of a mutation in a gene identified in FIG. 10.

15. The method of claim 14, wherein said gene is an EGFR gene.

16. The method of claim 1, wherein said molecular analysis comprises detecting expression of a gene identified in FIG. 10.

17. The method of claim 16, wherein said gene is EGFR, EGF, EpCAM, GA733-2, MUC-1, HER-2, or Claudin-7.

18. The method of claim 16, wherein said gene is EpCAM.

19. The method of claim 16, wherein said gene is EGFR or EGF.

20. The method of claim 16, wherein a level of expression of said gene is quantified.

21. The method of claim 1, wherein said morphological analysis comprises staining said one or more rare cells and performing bright-field imaging of said one or more stained rare cells.

22. The method of claim 1, wherein said molecular analysis comprises amplifying one or more genomic sequences from said one or more rare cells to generate genomic amplicons.

23. The method of claim 22, wherein said amplifying comprises tagging said one or more genomic sequences to generate tagged genomic amplicons.

24. The method of claim 23, wherein said tagged genomic amplicons comprise locator elements.

25. A method for diagnosing or prognosing cancer in a patient comprising:

(i) enriching a biological sample, obtained at a time point from said patient, for rare cells to obtain a rare cell-enriched biological sample;

(ii) splitting said rare cell-enriched biological sample obtained from said patient at a time point into a plurality of subsamples; and

(iii) performing a molecular analysis or a morphological analysis on one or more subsamples in said plurality of subsamples, wherein ten percent or more of the total number of cells in at least one of said one or more subsamples are rare cells, and a cancer diagnosis or prognosis for said patient is determined based on said molecular analysis or said morphological analysis.

26. The method of claim 25, wherein said one or more rare cells comprise an epithelial cell, a circulating tumor cell, an endothelial cell, or a stem cell.

27. The method of claim 26, wherein said one or more rare cells comprise an epithelial cell.

28. The method of claim 26, wherein at least one of said subsamples comprises one to about ten rare cells.

29. The method of claim 26, wherein said enriching comprises performing rare cell immunoaffinity separation on said biological sample.

30. The method of claim 29, wherein said rare cell immunoaffinity separation comprises flowing said biological sample through an array of obstacles coated with one or more antibodies that selectively bind to rare cells.

31. The method of claim 29, wherein said immunoaffinity separation comprises an EpCAM immunoaffinity separation.

32. The method of claim 25, wherein at least one of said subsamples in said plurality of subsamples occupies a discrete site.

33. The method of claim 25, wherein said molecular analysis comprises detecting said presence or absence of a mutation in a gene identified in FIG. 10.

34. The method of claim 33, wherein said gene is an EGFR gene.

35. The method of claim 25, wherein said molecular analysis comprises detecting expression of a gene identified in FIG. 10.

36. The method of claim 35, wherein said gene is EGFR, EGF, EpCAM, GA733-2, MUC-1, HER-2, or Claudin-7.

37. The method of claim 35, wherein said gene is EpCAM.

38. The method of claim 35, wherein said gene is EGFR or EGF.

39. The method of claim 35, wherein a level of expression of said gene is quantified.

40. The method of claim 25, wherein said morphological analysis comprises staining said one or more rare cells and performing bright-field imaging of said one or more stained rare cells.

41. The method of claim 25, wherein said molecular analysis comprises amplifying one or more genomic sequences from said one or more rare cells to generate genomic amplicons.

42. The method of claim 41, wherein said amplifying comprises tagging said one or more genomic sequences to generate tagged genomic amplicons.

43. The method of claim 42, wherein said tagged genomic amplicons comprise locator elements.

44. The method of claim 87, wherein said amplifying is followed by quantitative genotyping.

45. The method of claim 91, wherein said quantitative genotyping is performed using one or more molecular inversion probes.

46. A method of optimizing a cancer therapy for a patient, said method comprising:

(i) splitting a rare cell-enriched biological sample, obtained from said patient at a time point, into a plurality of subsamples containing one or more rare cells;

(ii) performing a molecular analysis on one or more subsamples of said plurality of subsamples; and

(iii) based on said molecular analysis;

(a) predicting efficacy of a cancer therapy treatment for said patient;

(b) selecting said cancer therapy treatment for said patient;

or

(c) excluding said cancer therapy treatment for said patient;

wherein

(i) said molecular analysis includes determining the presence or absence of a gene mutation in said one or more subsamples, (ii) ten percent or more of the total number of cells in at least one of said one or more subsamples are rare cells, and (iii) a cancer diagnosis or prognosis for said patient is determined based on said molecular analysis.

47. The method of claim 46, wherein said one or more rare cells comprises an epithelial cell, a circulating tumor cell, an endothelial cell, or a stem cell.

48. The method of claim 47, wherein said one or more rare cells comprises an epithelial cell.

49. The method of claim 46, wherein said rare cell-enriched biological sample was obtained by rare cell immunoaffinity separation of a biological sample from said patient.

50. The method of claim 46, wherein said immunoaffinity separation comprised flowing said biological sample from said patient through an array of obstacles coated with one or more antibodies that selectively bind to rare cells.

51. The method of claim 46, wherein said molecular analysis farther comprises computing a fraction of said plurality of subsamples that contain rare cells having said gene mutation.

52. The method of claim 46, wherein said gene mutation occurs in any of the genes listed in FIG. 10.

53. The method of claim 46, wherein said gene mutation occurs in the EGFR gene.

54. The method of claim 46, wherein said molecular analysis further comprises detecting expression of a gene identified in FIG. 10.

55. The method of claim 54, wherein said gene is EGFR, EGF, EpCAM, GA733-2, MUC-1, HER-2, or Claudin-7.

56. The method of claim 54, wherein said gene is EGFR or EGF.